glp-1 agonis and Anesthesia: Considerations and Cautions for CRNAs Emerging Frontiers in GLP-1 Therapeutics:

Common impurities to check include truncated peptide sequences (Gly-His or His-Lys fragments), residual coupling reagents and protecting groups, counterion residues, free (uncomplexed) GHK, and excess copper salts

We ask them to report their weight and any side effects every week and then each month, before their next shipment, theres a discussion with one of the study physicians about, okay, are you still having any side effects? Vogel said

However, BPC 157 remains experimental and is not FDA-approved for human medical use

Future outlook: what comes next for both compounds The peptide weight loss landscape is evolving rapidly, and both cagrilintide and retatrutide sit at the center of that evolution

The Journal of Allergy and Clinical Immunology